HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation

Jing Qi, Sandeep Singh, Wei Kai Hua, Qi Cai, Shi Wei Chao, Ling Li, Hongjun Liu, Yinwei Ho, Tinisha McDonald, Allen Lin, Guido Marcucci, Ravi Bhatia, Wei Jan Huang, Chung I. Chang, Ya Huei Kuo

研究成果: 雜誌貢獻文章同行評審

54 引文 斯高帕斯(Scopus)

摘要

Acute myeloid leukemia (AML) is driven and sustained by leukemia stem cells (LSCs) with unlimited self-renewal capacity and resistance to chemotherapy. Mutation in the TP53 tumor suppressor is relatively rare in de novo AML; however, p53 can be regulated through post-translational mechanisms. Here, we show that p53 activity is inhibited in inv(16)+ AML LSCs via interactions with the CBFβ-SMMHC (CM) fusion protein and histone deacetylase 8 (HDAC8). HDAC8 aberrantly deacetylates p53 and promotes LSC transformation and maintenance. HDAC8 deficiency or inhibition using HDAC8-selective inhibitors (HDAC8i) effectively restores p53 acetylation and activity. Importantly, HDAC8 inhibition induces apoptosis in inv(16)+ AML CD34+ cells, while sparing the normal hematopoietic stem cells. Furthermore, in vivo HDAC8i administration profoundly diminishes AML propagation and abrogates leukemia-initiating capacity of both murine and patient-derived LSCs. This study elucidates an HDAC8-mediated p53-inactivating mechanism promoting LSC activity and highlights HDAC8 inhibition as a promising approach to selectively target inv(16)+ LSCs.

原文英語
頁(從 - 到)597-610
頁數14
期刊Cell Stem Cell
17
發行號5
DOIs
出版狀態已發佈 - 十一月 5 2015

ASJC Scopus subject areas

  • 細胞生物學
  • 分子醫學
  • 遺傳學

指紋

深入研究「HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation」主題。共同形成了獨特的指紋。

引用此